Low-sodium diet induces atherogenesis regardless of lowering blood pressure in hypertensive hyperlipidemic mice

Carregando...
Imagem de Miniatura
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Citação
PLOS ONE, v.12, n.5, article ID e0177086, 22p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
This study investigated the influence of sodium restriction and antihypertensive drugs on atherogenesis utilizing hypertensive (H) low-density lipoprotein-receptor knockout mice treated or not with losartan (Los) or hydralazine (Hyd) and fed low-sodium (LS) or normal-sodium (NS) chow. Despite reducing the blood pressure (BP) of H-LS mice, the LS diet caused arterial lipid infiltration due to increased plasma total cholesterol (TC) and triglycerides (TG). Los and Hyd reduced the BP of H-LS mice, and Los effectively prevented arterial injury, likely by reducing plasma TG and nonesterified fatty acids. Aortic lipid infiltration was lower in Los-treated H-LS mice (H-LS+Los) than in normotensive (N)-LS and H-LS mice. Aortic angiotensin II type 1 (AT1) receptor content was greater in H-NS than H-LS mice and in H-LS+Hyd than H-LS+Los mice. Carboxymethyl-lysine (CML) and receptor for advanced glycation end products (RAGE) immunostaining was greater in H-LS than H-NS mice. CML and RAGE levels were lower in LS animals treated with antihypertensive drugs, and Hyd enhanced the AT1 receptor level. Hyd also increased the gene expression of F4/80 but not tumor necrosis factor-a, interleukin (IL)-1 beta, IL-6, IL-10, intercellular adhesion molecule-1 or cluster of differentiation 66. The novelty of the current study is that in a murine model of simultaneous hypertension and hyperlipidemia, the pleiotropic effect of chronic, severe sodium restriction elicited aortic damage even with reduced BP. These negative effects on the arterial wall were reduced by AT1 receptor antagonism, demonstrating the influence of angiotensin II in atherogenesis induced by a severely LS diet.
Palavras-chave
Referências
  1. Alderman MH, 2004, J AM SOC NEPHROL, V15, pS47, DOI 10.1097/01.ASN.0000093236.74397.F3
  2. Alderman MH, 2010, JAMA-J AM MED ASSOC, V303, P448, DOI 10.1001/jama.2010.69
  3. Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0
  4. Bouguerne B, 2011, ANTIOXID REDOX SIGN, V14, P2093, DOI 10.1089/ars.2010.3321
  5. BRENSILVER JM, 1985, KIDNEY INT, V27, P497, DOI 10.1038/ki.1985.38
  6. Catanozi S, 2003, J LIPID RES, V44, P727, DOI 10.1194/jlr.M200330-JLR200
  7. Catanozi S, 2001, ATHEROSCLEROSIS, V158, P81, DOI 10.1016/S0021-9150(01)00415-4
  8. Cheng C, 2006, CIRCULATION, V113, P2744, DOI 10.1161/CIRCULATIONHA.105.590018
  9. Curfs DMJ, 2004, AM J PATHOL, V164, P101, DOI 10.1016/S0002-9440(10)63101-X
  10. Daugherty A, 2004, CIRCULATION, V110, P3849, DOI 10.1161/01.CIR.0000150540.54220.C4
  11. Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P281, DOI 10.1089/ars.2012.4918
  12. Dikalov SI, 2013, ANTIOXID REDOX SIGN, V19, P1085, DOI 10.1089/ars.2012.4604
  13. Ferreira DN, 2010, J NUTR, V140, P1742, DOI 10.3945/jn.109.117473
  14. Fu MX, 1996, J BIOL CHEM, V271, P9982
  15. Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026
  16. Garg R, 2014, HYPERTENSION, V64, P1384, DOI 10.1161/HYPERTENSIONAHA.114.03880
  17. Garg R, 2011, METABOLISM, V60, P965, DOI 10.1016/j.metabol.2010.09.005
  18. Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
  19. Goel Reema, 2008, Arterioscler Thromb Vasc Biol, V28, P1996, DOI 10.1161/ATVBAHA.108.172270
  20. Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383
  21. Graudal NA, 2012, AM J HYPERTENS, V25, P1, DOI 10.1038/ajh.2011.210
  22. Humalda JK, 2014, CURR OPIN NEPHROL HY, V23, P533, DOI 10.1097/MNH.0000000000000073
  23. Ivanovski O, 2005, ATHEROSCLEROSIS, V180, P271, DOI 10.1016/j.athersclerosis.2004.12.020
  24. Johns C, 1996, HYPERTENSION, V28, P1064
  25. Kalea AZ, 2009, FASEB J, V23, P1766, DOI 10.1096/fj.08-117739
  26. KATSUTANI N, 1992, INT J IMMUNOPHARMACO, V14, P673, DOI 10.1016/0192-0561(92)90130-D
  27. Keidar S, 1999, ATHEROSCLEROSIS, V146, P249, DOI 10.1016/S0021-9150(99)00145-8
  28. Keidar S, 1997, BIOCHEM BIOPH RES CO, V236, P622, DOI 10.1006/bbrc.1997.6844
  29. Krikken JA, 2012, NUTR METAB CARDIOVAS, V22, P35, DOI 10.1016/j.numecd.2010.03.010
  30. Lichtman AH, 1999, ARTERIOSCL THROM VAS, V19, P1938
  31. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  32. Lopez-Diez R, 2013, GENOME BIOL EVOL, V5, P2420, DOI 10.1093/gbe/evt188
  33. MITCHELL JA, 1990, DRUG SAFETY, V5, P168, DOI 10.2165/00002018-199005030-00002
  34. Mouedden Mohammed El, 2007, Pharmacol Biochem Behav, V86, P458, DOI 10.1016/j.pbb.2007.01.003
  35. Nakandakare ER, 2008, ATHEROSCLEROSIS, V200, P410, DOI 10.1016/j.atherosclerosis.2007.12.034
  36. Nickenig G, 2000, BRIT J PHARMACOL, V131, P795, DOI 10.1038/sj.bjp.0703623
  37. Nickenig G, 1997, AM J PHYSIOL-HEART C, V272, pH2701
  38. PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4
  39. Rugale C, 2007, J CARDIOVASC PHARM, V50, P293
  40. RUPPERT M, 1994, AM J MED SCI, V307, pS87
  41. Stolarz-Skrzypek K, 2011, JAMA-J AM MED ASSOC, V305, P1777, DOI 10.1001/jama.2011.574
  42. Tikellis C, 2012, HYPERTENSION, V60, P98, DOI 10.1161/HYPERTENSIONAHA.112.191767
  43. National Research Council (US), 2011, GUIDE CARE USE LAB A
  44. Van Assche T, 2011, J VASC RES, V48, P31, DOI 10.1159/000317398
  45. Weiss D, 2001, CIRCULATION, V103, P448
  46. Wiesel P, 1997, HYPERTENSION, V29, P1025
  47. Zhang YH, 2014, J RENIN-ANGIO-ALDO S, V16, P292